Company Profile
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Latest News
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.oricpharma.com |
| Audit Risk | 10 |
| Board Risk | 6 |
| Overall Risk | 8 |
| Market Cap | 1.25B |
| Forward P/E | -7.49 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -1.39 |
| Forward EPS | -1.61 |
| Book Value | 4.02 |
| Price-to-Book | 3.01 |
| Enterprise-to-EBITDA | -6.57 |
| Short Ratio | 12.82 |
| Earnings Date | 08/11/2026 |
| Earnings Call Date | |
| Earnings Average | -0.36 |
| Earnings Low | -0.4 |
| Earnings High | -0.3 |
| Revenue Average | 0 |
| Revenue Low | 0 |
| Revenue High | 0 |